DNA sequencing

Source BioScience launches Sanger Sequencing Service in San Diego, CA to support life science researchers with market-leading genomic services

Retrieved on: 
Monday, August 22, 2022

With further plans for rapid growth in the Genomics space, Source will also soon be offering plasmid extraction and Next Generation Sequencing services as part of its portfolio.

Key Points: 
  • With further plans for rapid growth in the Genomics space, Source will also soon be offering plasmid extraction and Next Generation Sequencing services as part of its portfolio.
  • Source has already established close relationships with pharmaceutical and life science companies through its dedicated Stability Storage service.
  • Sanger Sequencing services are available via the Source BioScience website (us.sourcebioscience.com), providing access to top quality genomicservices with publication-ready data at unrivalled turnaround times.
  • In reflecting on the success of Source BioScience Sanger Sequencing Service in the UK, a customer from a leading research organization commented:"I started using Source BioScience after a recommendation and I am so pleased I switched.

Global miRNA Tools and Services Market Opportunity Analysis and Industry Forecasts, 2021-2031 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022

The "miRNA Tools and Services Market by Product and Services, Technology, End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "miRNA Tools and Services Market by Product and Services, Technology, End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global miRNA tools and services market was valued $311.86 million in 2021 and expected to reach $1,822.15 million by 2031, with a CAGR of 19.3% from 2022 to 2031.
  • It offers miRNA tools and services market analysis from 2021 to 2031, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • The profiles and growth strategies of the key players are thoroughly analysed to understand the competitive outlook and global miRNA tools and services market growth.

OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 11, 2022

Management conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT

Key Points: 
  • Management conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT
    ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen or the Company), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results.
  • Management will host an investor call to discuss quarterly results and provide a business update.
  • Second Quarter and First Half 2022 Financial Results of OpGen, Inc.
    Total revenue for the second quarter of 2022 was approximately $1.0 million, compared with approximately $0.8 million in the second quarter of 2021.
  • Operating expenses for the second quarter of 2022 were approximately $6.2 million, compared with approximately $7.0 million in the second quarter of 2021.

Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine

Retrieved on: 
Tuesday, August 9, 2022

SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE for genomic profiling in blood and urine.

Key Points: 
  • SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE for genomic profiling in blood and urine.
  • With this CE mark, Predicine can provide PredicineCARE as a commercialized in vitro diagnostic (IVD) in the European market.
  • PredicineCARE is the first urine-based cfDNA assay that is characterized by exceptional analytical performance and thus will provide great value to patients in Europe.
  • The Predicine portfolio includes blood-, urine-, and tissue-based NGS assays designed for global harmonized use in research, clinical investigation, and CDx development.

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

Retrieved on: 
Thursday, August 4, 2022

CLEVELAND, Aug. 4, 2022 /PRNewswire/ -- Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.

Key Points: 
  • CLEVELAND, Aug. 4, 2022 /PRNewswire/ -- Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.
  • To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with GenomOncology to provide regional therapy recommendations.
  • GenomOncology's Precision Oncology Platform is designed to harmonize the latest precision oncology information, which includes an extensive set of annotations and ontologies, as well as curated public, licensed, and proprietary content and data sets.
  • GenomOncology strengthens your precision oncology program by transforming valuable, but unusable data, into actionable oncology treatment options and strategic insights.

GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution

Retrieved on: 
Thursday, August 4, 2022

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.

Key Points: 
  • Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.
  • To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with GenomOncology to provide regional therapy recommendations.
  • GenomOncology brings extensive experience in precision oncology care, and its platform has been developed specifically to deliver clinical informatics solutions for cancer.
  • Our partnership with Congenica enables us to expand opportunities for precision oncology care at the global level.

Absolute Antibody Increases Automation Capabilities and Expands Production Facility to Support Continued Growth of its Recombinant Antibody Technology

Retrieved on: 
Wednesday, August 3, 2022

REDCAR, United Kingdom, Aug. 3, 2022 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the near doubling of its manufacturing facility in northeast England. The increased laboratory space includes a major investment in new automation for Next Generation Sequencing (NGS), expression and purification (HPLC) to enhance recombinant antibody production workflows. The additional space and equipment will enable Absolute Antibody to better service customers and accelerate the expansion of its recombinant antibody portfolio.

Key Points: 
  • The increased laboratory space includes a major investment in new automation for Next Generation Sequencing (NGS), expression and purification (HPLC) to enhance recombinant antibody production workflows.
  • The additional space and equipment will enable Absolute Antibody to better service customers and accelerate the expansion of its recombinant antibody portfolio.
  • "The increased space and automation is a direct result of the continued growth of our company and underlines our commitment to our clients and to advancing recombinant antibody technology," said Dr. Ed Horton, Chief Commercial Officer of Absolute Antibody.
  • Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all.

Global Biotechnology Market (2022-2027) by Technology, Application, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022

The "Global Biotechnology Market (2022-2027) by Technology, Application, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biotechnology Market (2022-2027) by Technology, Application, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Market dynamics are forces that impact the prices and behaviors of the Global Biotechnology Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Biotechnology Market.
  • The report analyses the Global Biotechnology Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.